Señales en vivo de ACRS | Maximiza tus Ganancias con Getagraph.com

COMPRAR 118678 min ago

@ $1.220

Emitido: 14 feb 2024 @ 10:55

Retorno: 7.38%

Señal anterior: feb 14 - 09:47

Señal anterior: Vender

Retorno: 0.00 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States...

Stats
Volumen de hoy	613 635
Volumen promedio	1.10M
Capitalización de mercado	93.36M
EPS	$-0.0200 ( 2024-02-29 )
Próxima fecha de ganancias	( $-0.280 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.030
ATR14	$0.00600 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Walker Neal	Buy	9 467	Common Stock
2024-05-01	Walker Neal	Sell	2 784	Common Stock
2024-05-01	Walker Neal	Sell	9 467	Restricted Stock Units
2024-04-01	Walker Neal	Buy	9 467	Common Stock
2024-04-01	Walker Neal	Sell	3 224	Common Stock

INSIDER POWER
76.35
Last 99 transactions
Buy: 2 282 071 \| Sell: 323 641

Volumen Correlación

Largo: 0.18 (neutral)

Corto: 0.58 (weak)

Signal:(55.472) Neutral

Aclaris Therapeutics Inc Correlación

10 Correlaciones Más Positivas
POET	0.958
AACG	0.946
GETVV	0.946
AVIR	0.946
NAKD	0.945
HLIO	0.944
IMPL	0.944
CRTO	0.944
HTCR	0.941
CMMB	0.94

10 Correlaciones Más Negativas
IDCC	-0.95
MPRA	-0.949
TZPSU	-0.947
CEG	-0.945
SLMBP	-0.945
STRA	-0.944
GALT	-0.944
CALB	-0.943
PRAA	-0.942
MEOH	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aclaris Therapeutics Inc Correlación - Moneda/Commodity

0.00
( neutral )

0.08
( neutral )

0.00
( neutral )

0.09
( neutral )

Aclaris Therapeutics Inc Finanzas

Annual	2023
Ingresos:	$31.25M
Beneficio Bruto:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2023
Ingresos:	$31.25M
Beneficio Bruto:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2022
Ingresos:	$29.75M
Beneficio Bruto:	$17.79M (59.80 %)
EPS:	$-1.360

FY	2021
Ingresos:	$6.76M
Beneficio Bruto:	$2.05M (30.29 %)
EPS:	$-2.14

Financial Reports:

No articles found.

Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Actualizaciones en tiempo real para Aclaris Therapeutics Inc [ACRS]

Upcoming Earnings Alert